FDA Oncology Advisory Committee to Weigh Exelixis’ Cabometyx in Neuroendocrine Tumours
The advisory committee will meet to discuss Cabometyx's phase 3 CABINET study in March 2025.
Before Exelexis’ Cabometyx can pass muster with the FDA in its hopefu...























